Back to News
Market Impact: 0.18
Augurex Announces Mayo Clinic Laboratories Now Offering 14-3-3eta Testing for Rheumatoid Arthritis
Source: Business Wire
Healthcare & BiotechProduct Launches
Mayo Clinic Laboratories now offers Augurex's 14-3-3eta serum test, a rheumatoid arthritis biomarker designed to complement RF and anti-CCP testing. The expanded availability could support earlier RA diagnosis, representing a modest positive commercial and clinical-validation milestone for Augurex.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Backbone of a beast – charting Nvidia's rise to networking titan
- Illumina CEO on Q3 Results and Business Outlook
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat
- Freedom Broker raises Eli Lilly stock price target on GLP-1 demand